Freitag Julien, Wickham James, Shah Kiran, Tenen Abi
School of Biomedical Science, Charles Sturt University, Orange, New South Wales, Australia.
Melbourne Stem Cell Centre, Box Hill North, Victoria, Australia.
BMJ Case Rep. 2019 Feb 27;12(2):e227865. doi: 10.1136/bcr-2018-227865.
The aim of this case report is to evaluate the efficacy of mesenchymal stem cell (MSC) therapy in the treatment of small joint osteoarthritis (OA). Acromio-clavicular (AC) joint OA is an under-diagnosed and yet frequent source of shoulder pain. MSCs have shown evidence of benefit in the treatment of knee OA. This is the first report to describe the use of MSC therapy in OA of the upper limb. A 43-year-old patient presents with painful AC joint OA and undergoes MSC therapy. The patient reported pain and functional improvement as assessed by the Disability of Arm, Shoulder and Hand Score and Numeric Pain Rating Scale. Imaging at 12 months showed structural improvement with reduction in subchondral oedema, synovitis and subchondral cysts. This case is the first to show the benefit of MSC therapy in the treatment of small joint arthropathy and also of the upper limb.Trial registration number: Australian New Zealand Clinical Trials Registry (ACTRN12617000638336).
本病例报告的目的是评估间充质干细胞（MSC）疗法治疗小关节骨关节炎（OA）的疗效。肩锁（AC）关节OA是一种诊断不足但常见的肩部疼痛来源。MSC已显示出对膝关节OA治疗有益的证据。这是第一份描述MSC疗法用于上肢OA治疗的报告。一名43岁患者因疼痛性AC关节OA接受了MSC疗法。患者报告称，根据手臂、肩部和手部功能障碍评分及数字疼痛评分量表评估，疼痛和功能得到改善。12个月时的影像学检查显示结构改善，软骨下水肿、滑膜炎和软骨下囊肿减少。该病例首次显示了MSC疗法在治疗小关节病以及上肢疾病方面的益处。试验注册号：澳大利亚新西兰临床试验注册中心（ACTRN12617000638336）。
